Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Stephane Navé
Sign up to set email alerts
29
Publications
363
Citation Statements Received
654
Citation Statements Given
How they've been cited
593
15
347
1
How they cite others
949
38
615
1
Affiliations
Roche (Switzerland)
,
Roche (France)
Publications
Order By: Most citations
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA
In Silico
Strategy
Li
1
,
Mirams
2
,
Yoshinaga
3
et al.
2019
Clin Pharma and Therapeutics
Abstract
Show
121
2
88
0
Get access via publisher
Add to collection
Cite
Contingent negative variation as a dopaminergic biomarker: evidence from dose-related effects of methylphenidate
Linssen
1
,
Vuurman
2
,
Sambeth
3
et al.
2011
Psychopharmacology
Abstract
Show
88
5
49
0
Get access via publisher
Add to collection
Cite
Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man
Hipp
1
,
Knoflach
2
,
Comley
3
et al.
2021
Sci Rep
Abstract
Show
48
2
51
0
Get access via publisher
Add to collection
Cite
Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer’s Disease
Borroni
1
,
Bohrmann
2
,
Grueninger
3
et al.
2017
The Journal of Pharmacology and Experimental Therapeutics
Abstract
Show
86
2
37
1
Get access via publisher
Add to collection
Cite
Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)
Navé
1
,
Doody
2
,
Boada
3
et al.
2017
Journal of Alzheimer’s Disease
Abstract
Show
49
2
38
0
Get access via publisher
Add to collection
Cite
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
Sergott
1
,
Amorelli
2
,
Baranello
3
et al.
2020
Ann Clin Transl Neurol
Abstract
Show
40
1
23
0
Get access via publisher
Add to collection
Cite
The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects
Weber
1
,
Banken
2
,
Birnboeck
3
et al.
1999
Brit J Clinical Pharma
Abstract
Show
31
0
16
0
Get access via publisher
Add to collection
Cite
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline
Sturm
1
,
Forsberg
2
,
Navé
3
et al.
2016
Eur J Nucl Med Mol Imaging
Abstract
Show
26
0
15
0
Get access via publisher
Add to collection
Cite
1
2
3